DORA Metastatic Prostate Cancer Trial
Protocol: STUDY00004812
Full Title
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Description
This study enrolls men with prostate cancer. The purpose of this study is to compare using radium-223 and docetaxel chemotherapy treatment vs. using docetaxel alone in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Radium223 has been FDA approved to treat men with prostate cancer that has spread to the bone, but it has not been approved for men with cancer that has spread to soft tissue or in combination with the chemotherapy drug docetaxel.

You will take the study drugs for about 8 months, which will include follow up visits. After that, your doctor will call to see how you are doing every 6 months. You will be randomly assigned, like the flip of a coin, to take either docetaxel or docetaxel and prednisone plus radium-223.

Please contact our team for more details about this study and to learn if you or a loved one may be eligible.
Compensation: No
Eligibility
Adults ages 18+.
Males with progressive Metastatic Prostate Cancer.
Have 2+ bone lesions.
Age Group: Adults
Principal Investigator: ROBERTO PILI
ClinicalTrials.gov: Open Study
Contact(s)
Jessica McCarthy
jm279@buffalo.edu
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.